Cargando…
Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer
SIMPLE SUMMARY: The study compares the effects on complete remission rate (CR) of a single dose of durvalumab/tremelimumab immediately after a single-cycle platinum and docetaxel as part of induction therapy for a controlled trial in head and neck cancer with chemotherapy alone from a historical col...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073509/ https://www.ncbi.nlm.nih.gov/pubmed/33921668 http://dx.doi.org/10.3390/cancers13081959 |
_version_ | 1783684146723291136 |
---|---|
author | Semrau, Sabine Gostian, Antoniu-Oreste Traxdorf, Maximilian Eckstein, Markus Rutzner, Sandra von der Grün, Jens Illmer, Thomas Hautmann, Matthias Klautke, Gunther Laban, Simon Brunner, Thomas Tamaskovics, Bálint Frey, Benjamin Zhou, Jian-Guo Geppert, Carol-Immanuel Hartmann, Arndt Balermpas, Panagiotis Budach, Wilfried Gaipl, Udo Iro, Heinrich Fietkau, Rainer Hecht, Markus |
author_facet | Semrau, Sabine Gostian, Antoniu-Oreste Traxdorf, Maximilian Eckstein, Markus Rutzner, Sandra von der Grün, Jens Illmer, Thomas Hautmann, Matthias Klautke, Gunther Laban, Simon Brunner, Thomas Tamaskovics, Bálint Frey, Benjamin Zhou, Jian-Guo Geppert, Carol-Immanuel Hartmann, Arndt Balermpas, Panagiotis Budach, Wilfried Gaipl, Udo Iro, Heinrich Fietkau, Rainer Hecht, Markus |
author_sort | Semrau, Sabine |
collection | PubMed |
description | SIMPLE SUMMARY: The study compares the effects on complete remission rate (CR) of a single dose of durvalumab/tremelimumab immediately after a single-cycle platinum and docetaxel as part of induction therapy for a controlled trial in head and neck cancer with chemotherapy alone from a historical collective. The CR rate was 60.3% after induction chemoimmunotherapy (ICIT; induction chemotherapy plus double immune checkpoint blockade) compared with 40.3% after induction chemotherapy (IC) alone. Patients with HPV-positive oropharyngeal cancer may benefit the most from additive double checkpoint inhibition, which is presumably due to the higher amount of infiltrating immune cells. Patients older than 60 years without HPV-positive oropharyngeal cancer are unlikely to benefit. ABSTRACT: To determine whether a single dose of double immune checkpoint blockade (induction chemoimmunotherapy (ICIT)) adds benefit to induction single-cycle platinum doublet (induction chemotherapy (IC)) in locally advanced head and neck squamous cell carcinoma (HNSCC), patients treated with cisplatin 30 mg/m(2) d1-3 and docetaxel 75 mg/m(2) d1 combined with durvalumab 1500 mg fixed dose d5 and tremelimumab 75 mg fixed dose d5 (ICIT) within the CheckRad-CD8 trial were compared with a retrospective cohort receiving the same chemotherapy (IC) without immunotherapy. The endpoint of this analysis was the complete response rate (CR). A total of 53 patients were treated with ICIT and 104 patients with IC only. CR rates were 60.3% for ICIT and 40.3% for IC (p = 0.018). In the total population (n = 157), the most important predictor to achieve a CR was treatment type (OR: 2.21 for ICIT vs. IC; p = 0.038, multivariate analysis). The most diverse effects in CR rates between ICIT and IC were observed in younger (age ≤ 60) patients with HPV-positive OPSCCs (82% vs. 33%, p = 0.176), while there was no difference in older patients without HPV-positive OPSCCs (53% vs. 48%). The analysis provides initial evidence that ICIT could result in higher CR rates than IC. Young patients with HPV-positive OPSCCs may have the greatest benefit from additional immune checkpoint inhibitors. |
format | Online Article Text |
id | pubmed-8073509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80735092021-04-27 Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer Semrau, Sabine Gostian, Antoniu-Oreste Traxdorf, Maximilian Eckstein, Markus Rutzner, Sandra von der Grün, Jens Illmer, Thomas Hautmann, Matthias Klautke, Gunther Laban, Simon Brunner, Thomas Tamaskovics, Bálint Frey, Benjamin Zhou, Jian-Guo Geppert, Carol-Immanuel Hartmann, Arndt Balermpas, Panagiotis Budach, Wilfried Gaipl, Udo Iro, Heinrich Fietkau, Rainer Hecht, Markus Cancers (Basel) Article SIMPLE SUMMARY: The study compares the effects on complete remission rate (CR) of a single dose of durvalumab/tremelimumab immediately after a single-cycle platinum and docetaxel as part of induction therapy for a controlled trial in head and neck cancer with chemotherapy alone from a historical collective. The CR rate was 60.3% after induction chemoimmunotherapy (ICIT; induction chemotherapy plus double immune checkpoint blockade) compared with 40.3% after induction chemotherapy (IC) alone. Patients with HPV-positive oropharyngeal cancer may benefit the most from additive double checkpoint inhibition, which is presumably due to the higher amount of infiltrating immune cells. Patients older than 60 years without HPV-positive oropharyngeal cancer are unlikely to benefit. ABSTRACT: To determine whether a single dose of double immune checkpoint blockade (induction chemoimmunotherapy (ICIT)) adds benefit to induction single-cycle platinum doublet (induction chemotherapy (IC)) in locally advanced head and neck squamous cell carcinoma (HNSCC), patients treated with cisplatin 30 mg/m(2) d1-3 and docetaxel 75 mg/m(2) d1 combined with durvalumab 1500 mg fixed dose d5 and tremelimumab 75 mg fixed dose d5 (ICIT) within the CheckRad-CD8 trial were compared with a retrospective cohort receiving the same chemotherapy (IC) without immunotherapy. The endpoint of this analysis was the complete response rate (CR). A total of 53 patients were treated with ICIT and 104 patients with IC only. CR rates were 60.3% for ICIT and 40.3% for IC (p = 0.018). In the total population (n = 157), the most important predictor to achieve a CR was treatment type (OR: 2.21 for ICIT vs. IC; p = 0.038, multivariate analysis). The most diverse effects in CR rates between ICIT and IC were observed in younger (age ≤ 60) patients with HPV-positive OPSCCs (82% vs. 33%, p = 0.176), while there was no difference in older patients without HPV-positive OPSCCs (53% vs. 48%). The analysis provides initial evidence that ICIT could result in higher CR rates than IC. Young patients with HPV-positive OPSCCs may have the greatest benefit from additional immune checkpoint inhibitors. MDPI 2021-04-19 /pmc/articles/PMC8073509/ /pubmed/33921668 http://dx.doi.org/10.3390/cancers13081959 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Semrau, Sabine Gostian, Antoniu-Oreste Traxdorf, Maximilian Eckstein, Markus Rutzner, Sandra von der Grün, Jens Illmer, Thomas Hautmann, Matthias Klautke, Gunther Laban, Simon Brunner, Thomas Tamaskovics, Bálint Frey, Benjamin Zhou, Jian-Guo Geppert, Carol-Immanuel Hartmann, Arndt Balermpas, Panagiotis Budach, Wilfried Gaipl, Udo Iro, Heinrich Fietkau, Rainer Hecht, Markus Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer |
title | Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer |
title_full | Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer |
title_fullStr | Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer |
title_full_unstemmed | Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer |
title_short | Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer |
title_sort | implementation of double immune checkpoint blockade increases response rate to induction chemotherapy in head and neck cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073509/ https://www.ncbi.nlm.nih.gov/pubmed/33921668 http://dx.doi.org/10.3390/cancers13081959 |
work_keys_str_mv | AT semrausabine implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT gostianantoniuoreste implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT traxdorfmaximilian implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT ecksteinmarkus implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT rutznersandra implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT vondergrunjens implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT illmerthomas implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT hautmannmatthias implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT klautkegunther implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT labansimon implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT brunnerthomas implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT tamaskovicsbalint implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT freybenjamin implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT zhoujianguo implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT geppertcarolimmanuel implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT hartmannarndt implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT balermpaspanagiotis implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT budachwilfried implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT gaipludo implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT iroheinrich implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT fietkaurainer implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer AT hechtmarkus implementationofdoubleimmunecheckpointblockadeincreasesresponseratetoinductionchemotherapyinheadandneckcancer |